Market Intelligence, Clinical Progress, and High-Purity Reagents for Severe Asthma and Eosinophilic Disorder Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for IL-5RA drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IL-5RA ECD-Fc Recombinant Protein High purity (>95%), Endotoxin controlled (<1.0 EU/μg). Sequence Verified. HEK293 expressed for native glycosylation. |
View IL5RA Products |
| Gene Delivery | IL-5RA Promise-ORF / Lentivirus Full-length human IL-5RA ORF for stable cell line development and cell-based functional assays. |
View IL5RA Products |
| Benchmark Ab | Anti-IL-5RA Recombinant Antibody Recombinant positive control derived from Benralizumab sequence for binding and ADCC benchmarking. |
View IL5RA Products |
| Validator | IL-5RA siRNA Set Target-specific siRNA pool for target knockdown validation in primary eosinophils or cell lines. |
View IL5RA Products |
| Related Target A | IL-5 The primary ligand for IL-5RA. Crucial for ligand-blocking assays and synergistic pathway studies. |
View IL5 Products |
| Related Target B | CSF2RB The common beta subunit (βc) that heterodimerizes with IL-5RA to initiate downstream JAK/STAT signaling. |
View CSF2RB Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human and Cynomolgus IL-5RA ortholog proteins available with >95% purity verified by SDS-PAGE. |
| Soluble decoy receptor (sIL-5RA) interference | High-affinity monomeric and dimeric (Fc-fusion) IL-5RA proteins for precise competitive binding profiling. |
| Lack of Controls | Clinical Benchmark Antibodies (Benralizumab biosimilar) sequence-verified and expression-optimized. |
| False Positives | Validated siRNA sets included for target specificity and knock-down verification in phenotypic assays. |
Live IL-5RA R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the IL-5/IL-5RA axis has revolutionized the management of severe eosinophilic asthma. While first-generation therapies like Mepolizumab and Reslizumab target the soluble IL-5 ligand, Benralizumab (AstraZeneca) directly targets IL-5RA (CD125), utilizing an afucosylated Fc domain to induce antibody-dependent cell-mediated cytotoxicity (ADCC) for rapid eosinophil depletion. The next wave of R&D is shifting toward long-acting formulations, bispecific antibodies targeting dual inflammatory pathways (such as IL-5RA/IL-4R or IL-5RA/TSLP), and broadening indications to chronic obstructive pulmonary disease (COPD), bullous pemphigoid, and eosinophilic esophagitis (EoE).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADCC-Enhanced mAb | AstraZeneca, Kyowa Kirin | Severe Eosinophilic Asthma, COPD, HES | ADCC Reporter Assays (Need stable IL-5RA overexpressing cell lines via Lentivirus) |
| Bispecific Antibodies | Biopharma Innovators | Atopic Dermatitis, Severe Asthma | Dual-binding kinetics validation (Need high-purity monomeric IL-5RA and partner antigens) |
| Small Molecule Inhibitors | Academic & Biotech Startups | Eosinophilic Esophagitis (EoE) | Protein-protein interaction (PPI) disruption assays (Need highly stable IL-5RA/CSF2RB complex components) |